Uniphar (DUB:UPR) Total Equity: €405 Mil (As of Dec. 2025)


DUB:UPR Uniphar PLC DUB:UPR
82 GF Score
Price €4.57
GF Value €3.64
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is Uniphar Total Equity?

Uniphar DUB:UPR -0.65% 82 Total Equity is €405 Mil as of Dec. 2025. GuruFocus rates DUB:UPR with a GF Score™ of 82/100 and a GF Value™ of €3.64 (Modestly Overvalued). The stock has 9 warning signs investors should review.

Uniphar's total equity for the quarter that ended in Dec. 2025 was €405 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Uniphar Total Equity Historical Data

* Premium members only.

The historical data trend for Uniphar's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Uniphar Total Equity Chart

Uniphar Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 251.56 289.78 333.62 401.88 405.17

Uniphar Semi-Annual Data
Dec16 Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 333.62 350.19 401.88 372.98 405.17
DUB:UPR
82GF Score
Uniphar PLC DUB:UPR
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Uniphar Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Uniphar's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1732.259-1327.093
=405

Uniphar's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1732.259-1327.093
=405

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €405 Mil mean?
Uniphar (DUB:UPR) has a Total Equity of €405 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Uniphar and its competitors.
Is Uniphar's Total Equity too high?
Uniphar's current Total Equity is €405 Mil. Overall, Uniphar has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Uniphar's Total Equity compare to MCK and CAH?
Uniphar's Total Equity of €405 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Distribution company?
A good Total Equity depends on the Medical Distribution industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Uniphar and its competitors. Uniphar's current Total Equity is €405 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Uniphar stock overvalued right now?
Based on GuruFocus' analysis, Uniphar (DUB:UPR) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.64, compared to a current price of €4.57 — trading 25.5% above its estimated fair value. The current Total Equity is €405 Mil. Uniphar's overall GF Score™ is 82/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Uniphar (DUB:UPR), the current Total Equity is €405 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Uniphar (DUB:UPR) Overvalued in 2026?

Based on GuruFocus' analysis, Uniphar stock appears to be overvalued. The current stock price of €4.57 is trading 25.5% above its estimated GF Value™ of €3.64. GuruFocus considers Uniphar to be Modestly Overvalued.

Key valuation signals for DUB:UPR:

  • Total Equity: €405 Mil
  • GF Value™: €3.64 vs. price of €4.57 (25.5% above fair value)
  • GF Score™: 82/100 with 9 warning signs

No single metric tells the full story. See the DUB:UPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Uniphar Business Description

Other Exchanges UPR:UK0NR:Germany
Address 4045 Kingswood Road, Citywest Business Park, Dublin, IRL, D24 V06K
Uniphar PLC is a service provider within the pharmaceutical and healthcare sector. The company is an international diversified healthcare services business servicing the requirements of multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. Uniphar Pharma enables pharma and biotech companies to bring medicines to markets globally and provide healthcare professionals with access to medicines that can't be sourced through traditional channels. Uniphar Medtech is a Pan-European medical device distributor and solutions partner. Uniphar Supply Chain & Retail is the pharmaceutical wholesaler in Ireland offering of retail pharmacies.
82GF Score

Get the complete analysis for DUB:UPR

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.57
Price
€3.64
GF Value